Proteome Sciences (PI2) AI Stock Analysis

0 Followers

Proteome Sciences

(Frankfurt:PI2)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Specialized Proteomics OfferingThe company operates in a specialized proteomics niche that directly supports drug discovery and biomedical research. Its combination of analytical services, mass spectrometry workflows, and bioinformatics gives it a defined offering for pharmaceutical, biotechnology, and academic customers over the medium term.

Negative Factors

Severe Solvency PressureThe combination of rising debt, deeply negative equity, and assets below total debt indicates a capital structure under significant strain. This reduces financial flexibility and leaves the company more exposed to refinancing requirements, potential dilution, and constraints on funding its operating plans.

Proteome Sciences (PI2) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 4.54M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -1.8
Beta (1Y): -4.60
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 32
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Specialties

Proteome Sciences Business Overview & Revenue Model

Company Description

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standa...

Proteome Sciences Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:PI2 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:GDR	49Neutral	GBP 14.45M	-0.82	-1044.57%	―	65.60%	74.84%
GB:CLBX	48Neutral	GBP 6.82M	-0.49	-104.73%	―	-56.10%	41.10%
GB:GENI	40Underperform	GBP 4.52M	-0.43	-481.34%	―	-10.81%	42.67%
GB:OPTI	32Underperform	GBP 4.70M	-1.10	-77.85%	―	11.90%	-2864.29%
GB:VRCI	32Underperform	GBP 13.66M	-0.53	-127.57%	―	77.87%	84.36%

* Healthcare Sector Average

Performance Comparison

DE:PI2 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:PI2	Proteome Sciences	0.03	0.02	153.85%
GB:CLBX	ANGLE plc	0.60	-1.20	-66.67%
GB:GDR	Genedrive plc	0.90	0.11	13.92%
GB:OPTI	OptiBiotix Health	4.55	-3.70	-44.85%
GB:VRCI	Verici Dx Plc	0.20	-0.57	-73.55%
GB:GENI	GENinCode UK Ltd.	0.58	-1.72	-74.78%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Proteome Sciences AI Stock Analysis